C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B
TechCrunch
APRIL 15, 2021
C2i Genomics has developed software that’s 100x more sensitive in detecting residual disease, and investors are pouncing on the potential. Historically, the main approach to cancer detection post-surgery has been through the use of MRI or X-ray, but neither of those methods gets super accurate until the cancer progresses to a certain point.
Let's personalize your content